argenx Reports First Quarter 2025 Financial Results and Provides Business Update

About this update from Argenx Se

[{"type":"image","alt":"argenx SE","displaySize":"","headline":null,"caption":"argenx SE","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":97,"url":"https://media.zenfs.com/en/globenewswire.com/f35a3a919b58945aa6a1a93a9b760119"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_55.hEettGltaZ5cA.9xTw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f35a3a919b58945aa6a1a93a9b760119","width":300,"height":97}},"lazy":false},{"type":"text","content":"$790 million in first quarter global product net sales ","length":54,"tagName":"p"},{"type":"text","content":"First patients treated with VYVGART Hytrulo pre-filled syringe for self-injection in US and Germany ","length":99,"tagName":"p"},{"type":"text","content":"CIDP global expansion with positive CHMP opinion for VYVGART-SC (vial and pre-filled syringe) in EU ","length":99,"tagName":"p"},{"type":"text","content":"Management to host conference call today at 2:30 PM CET (8:30 AM ET) ","length":68,"tagName":"p"},{"type":"text","content":"May 8, 2025, 7:00 AM CET","length":24,"tagName":"p"},{"type":"text","content":"Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its first quarter 2025 financial results and provided a business update.","length":272,"tagName":"p"},{"type":"text","content":"“We continue to execute on our bold innovation agenda, guided by our ‘Vision 2030’ to reach 50,000 patients across 10 labeled indications,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx. “We remain committed to delivering meaningful outcomes with VYVGART by setting a new benchmark for sustained efficacy and safety, and generating data that matter most to improving the lives of patients. This strategy has driven strong launch fundamentals to date, and we see consistent patient and prescriber expansion in both gMG and CIDP. Looking forward, we have several reasons to be confident in our growth trajectory. We are thrilled to bring even more optionality to gMG and CIDP patients with the recent approval of our pre-filled syringe for self-injection in the United States, receiving an optimal label that supports our ability to reach patients earlier in the treatment paradigm. In line with ou...

More updates from Argenx Se